81. [Effects of Intensity of Acting Agents on the Manifestation of Synergistic Interaction].
The universal dependence of the synergistic interaction on the intensity of the acting agents was demonstrated. This dependence is not associated with the biological object, as well as the nature of the physical or chemical agents used in the combined exposures. In all cases, with a decrease in the intensity of one of the agents the intensity of the other factor should be also decreased to ensure the greatest synergistic effect. Such relationship of synergy and the intensity of the acting agents is of interest for radiation safety. This regularity indicates the principal possibility of synergistic interaction of harmful environmental factors actually occurring in the biosphere at their low intensities.
82. [The Combined Effects of Ionizing Radiation and Dendritic Polymers Loaded with Doxorubicin on the MCF-7 Breast Cancer Cell Line].
作者: I A Zamulaeva.;K A Pronyushkina.;O N Matchuk.;N G Yabbarov.;E D Nikolskaya.;I G Kondrasheva.
来源: Radiats Biol Radioecol. 2015年55卷6期591-7页
The dendritic polymers (dendrimers) are perspective nanocontainers for transportation of anticancer drugs into cells and a controlled release of the delivered substances. However, the combined effect of ionizing radiation and dendrimers loaded with anticancer drugs has been poorly studied and is the aim of this research. We used poliamidoamin (PAMAM) dendrimers of the second generation (G2) covalently conjugated with doxorubicin (Dox) via an acid labile linker, cis-aconitic anhydride. We compared the intracellular accumulation of Dox and growth rate of the MCF-7 cell culture under the single and combined action of ionizing radiation at a dose of 4 Gy, free Dox and G2-Dox. It was found that within 2 hours free Dox accumulated in cancer cells better than Dox connected with G2 dendrimers (p < 0.05 in the concentration range of 1-5 μmol/l). The intracellular accumulation of Dox was higher by 1.7 times for the free Dox than that connected with dendrimers (for concentration 0.5 μmol/l p = 0.02) after 26 hours of incubation. Like the intracellular accumulation of Dox, inhibition of the cell culture growth was more pronounced when using free Dox than G2-Dox in the case of both a single and combined action of these drugs. Subadditivity effects of the combined action of both drugs and ionizing radiation are shown in terms of reducing the number of tumor cells 24 hours after irradiation. The results indicate the need for further development of selective delivery systems for Doxin tumor cells, providing a more intense accumulation of anticancer drug in target cells.
83. [Effect of Conditioned Medium from Endothelial Cells on Cancer Stem Cell Phenotype of Hepatoma Cells].
作者: Chuan Feng.;Xianjiong Yang.;Jinghui Sun.;Qing Luo.;Guanbin Song.
来源: Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2015年32卷5期1061-6页
In this study, we aimed to investigate the influences of conditioned medium from human umbilical vein endothelial cells (HUVEC) on cancer stem cell phenotype of human hepatoma cells. HUVEC and human hepatoma cells (MHCC97H) were cultured, respectively, and then the MHCC97H cells were co-cultured with conditioned medium from HUVEC (EC-CM) with Transwell system. Anti-cancer drug sensitivity, colony-formation, migration/invasion ability, expression of cancer stem cell marker and sphere formation were performed to determine the cancer stem cell phenotype in MHCC97H cells. We found that MHCC97H cells co-cultured with EC-CM exhibited significantly higher colony-formation ability and lower sensitivity of anti-cancer drugs 5-FU and Cis. Transwell assay showed that treatment with EC-CM obviously increased migration and invasion of MHCC97H cells. Moreover, increased sphere forming capability and expression of CD133 in MHCC97H cells were observed after co-cultured with EC-CM. These results suggested that EC-CM could promote cancer stem cell phenotype of hepatoma cells.
84. Clinical outcome of patients with primary gliosarcoma treated with concomitant and adjuvant temozolomide: A single institutional analysis of 27 cases.
作者: G K Rath.;D N Sharma.;S Mallick.;A K Gandhi.;N P Joshi.;K P Haresh.;S Gupta.;P K Julka.
来源: Indian J Cancer. 2015年52卷4期599-603页
The prognosis of primary gliosarcoma (PGS) remains dismal with current treatment modalities. We analyzed the outcome of PGS patients treated with concurrent and adjuvant temozolomide (TMZ).
85. Bortezomib in newly diagnosed patients with multiple myeloma: A retrospective analysis from a tertiary care center in India.
Bortezomib is a novel proteasome inhibitor in myeloma. There is a paucity of data from India regarding the efficacy and tolerance to bortezomib.
86. [Synergistic inhibitory effect of static magnetic field and antitumor drugs on Hepa1-6 cells].
作者: Lingling Xu.;Wei Guo.;Ying Liu.;Xueqing Zhang.;Juntao Yu.;Wencai Wu.;Tiejun Zhao.
来源: Sheng Wu Gong Cheng Xue Bao. 2015年31卷9期1363-74页
Chemotherapy as a routine method for clinical treatment of cancer has disadvantages such as significant toxicity and strong resistance. In order to improve the efficacy of the drugs and reduce the by-effects, we tried to combine static magnetic field (SMF) with cisplatin or adriamycin. The growth of Hepa1-6 cells treated with the static magnetic field (SMF) combined with cisplatin or adriamycin was significantly inhibited, as detected with MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide) test. Combined treatment group cells underwent significant morphological changes as observed by HE (Hematoxylin and eosin) staining under optical microscope. Cell cycle analysis indicated that SMF increased the ratio of cells arrested in G2/M phase caused by cisplatin, and when treated with SMF combined with adriamycin, cells were almost arrested in G1 and G2/M phase. SCGE test showed that SMF can enhance the ability of cisplatin or adriamycin to promote cell DNA damage. Atomic force microscope observation found that the combination of antitumor drugs and magnetic field treatment induced larger and deeper holes on the cell membrane, and surface structure damage is serious. The combination of antitumor drugs and magnetic field technology effectively inhibits the growth of tumor cells, and reduces drug doses. The results implicate this method as potential cancer therapy.
87. Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma.
作者: Tony J C Wang.;Cheng-Chia Wu.;Ashish Jani.;Juan Estrada.;Timothy Ung.;Daniel S Chow.;Jennifer E Soun.;Shumaila Saad.;Yasir H Qureshi.;Robyn Gartrell.;Heva J Saadatmand.;Anurag Saraf.;Matthew D Garrett.;Christopher Grubb.;Steven R Isaacson.;Simon K Cheng.;Michael B Sisti.;Jeffrey N Bruce.;Sameer A Sheth.;Andrew B Lassman.;Fabio M Iwamoto.;Guy M McKhann.
来源: Pract Radiat Oncol. 2016年6卷5期306-314页
Adjuvant hypofractionated radiation therapy (HRT) for elderly patients with newly diagnosed glioblastoma (GBM) is a reasonable option compared with standard fractionation radiation therapy (SFRT). Outcomes in patients receiving HRT in the presence of temozolomide (TMZ) compared with SFRT with TMZ are unclear. We examined HRT for GBM with TMZ in comparison to SFRT with TMZ.
88. An exploratory study on the effectiveness of "Calmare therapy" in patients with cancer-related neuropathic pain: A pilot study.
作者: Sang Chul Lee.;Keun Suk Park.;Jee Youn Moon.;Eun Jung Kim.;Yong-Chul Kim.;Hyejin Seo.;Joon Kyung Sung.;Da Jeong Lee.
来源: Eur J Oncol Nurs. 2016年21卷1-7页
Calmare therapy (CT) has been suggested as a novel treatment for managing chronic pain. Recently, it was reported to show a positive therapeutic outcome for managing neuropathic pain condition. We performed an exploratory prospective study on the effectiveness of CT in patients with various types of cancer-related neuropathic pain (CNP).
90. Safe handling and administration of MABS: the guidance.
While monoclonal antibodies (MABs) are not as hazardous as cytotoxic drugs, there is concern among health professionals about the potential risks and the limited evidence about this. Guidance on the safe use of MABs is mainly to be found in national documents covering all systemic anti-cancer therapies, with the only consensus guidelines specifically on MABs coming from Australia. This article therefore summarises the existing guidance relating to MABs.
91. Neurotoxicity to DRG neurons varies between rodent strains treated with cisplatin and bortezomib.
作者: Jewel L Podratz.;Amit Kulkarni.;Josef Pleticha.;Rahul Kanwar.;Andreas S Beutler.;Nathan P Staff.;Anthony J Windebank.
来源: J Neurol Sci. 2016年362卷131-5页
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose limiting side effect that can lead to long-term morbidity. Approximately one-third of patients receiving chemotherapy with taxanes, vinca alkaloids, platinum compounds or proteasome inhibitors develop this toxic side effect. It is not possible to predict who will get CIPN, however, genetic susceptibility may play a role. We explored this hypothesis using an established in vitro dorsal root ganglia neurite outgrowth (DRG-NOG) assay to assess possible genetic influences for cisplatin- and bortezomib-induced neurotoxicity. Almost all previous in vitro studies have used rats or mice. We compared DRG-NOG between four genetically defined, inbred mouse strains (C57BL/6J, DBA/2J, BALB/cJ, and C3H/HeJ) and one rat strain (Sprague Dawley). Our studies found differences in cisplatin and bortezomib-induced neurotoxicity between mouse and rat strains and between the different mouse strains. C57BL/6J and Balb/cJ DRG-NOG was more sensitive to cisplatin than DBA/2J and C3H/HeJ DRG-NOG, and all mouse strains were more sensitive to cisplatin than rat. Bortezomib induced a biphasic dose response in DBA/2J and C3H/H3J mice. C57BL/6J DRG-NOG was most sensitive and Balb/cJ DRG-NOG was least sensitive to bortezomib. Our animal data supports the hypothesis that genetic background may play a role in CIPN and care must be taken when rodent models are used to better understand the contribution of genetics in patient susceptibility to CIPN.
93. Treatment of bladder urothelium injury.
The management of patients with cystitis-related symptoms due to urinary tract infection, bladder pain syndrome (BPS) or radio/chemo-induced cystitis remains challenging. A component in the pathophysiology of these symptoms relates to the fact that the urothelium is a highly metabolically active structure and that alterations in this structure can give rise to a variety of symptoms.
94. Chemotherapy and pelvic radiotherapy-induced bladder injury.
An understanding of the basics of the anatomy of the bladder mucosa is essential to better understand the pathophysiology of chemo-and radiotherapy-induced cystitis. Following an overview of bladder anatomy and the definitions and causes of bladder injury, the mechanisms of cyclophosphamide (CP)-induced bladder injury are discussed as a specific example.
96. A New Role for an Old Drug: Metformin Targets MicroRNAs in Treating Diabetes and Cancer.
MicroRNAs (miRNAs) are a family of short, noncoding, 19-23 base pair RNA molecules. Due to their unique role in gene regulation in various tissues, miRNAs play important roles in regulating insulin secretion, metabolic disease, and cancer biology. Emerging evidence demonstrates that miRNAs could also be novel diagnostic markers for a variety of disease states. Additionally, miRNAs have been found to function either as oncogenes, or tumor suppressor genes in cerian cancers. An increasing number of studies have been conducted investigating new drugs targeting miRNAs as a potential anticancer therapy. Metformin is the most widely prescribed medication for treating Type 2 diabetes (T2D). Recent clinical data suggests that metformin impacts the miRNA profile in T2D subjects. Most excitingly, studies have found that metformin is protective against cancer. The anticancer activity of metformin is mediated through a direct regulation of miRNAs, which further modulates several downstream genes in metabolic or preoncogenic pathways. These miRNAs are, therefore, prospective therapeutic targets for treating diabetes and cancer which is the topic of this review. Further study on the regulation of miRNAs by metformin could result in novel therapeutic strategies for recurrent or drug-esistant cancer, and as part of combinatorial approaches with conventional anticancer therapies.
97. Protease-activated receptors (PARs) in cancer: Novel biased signaling and targets for therapy.
作者: R Bar-Shavit.;M Maoz.;A Kancharla.;M Jaber.;D Agranovich.;S Grisaru-Granovsky.;B Uziely.
来源: Methods Cell Biol. 2016年132卷341-58页
Despite the fact that G protein-coupled receptors (GPCRs) mediate numerous physiological processes and represent targets for therapeutics for a vast array of diseases, their role in tumor biology is under appreciated. Protease-activated receptors (PARs) form a family which belongs to GPCR class A. PAR1&2 emerge with a central role in epithelial malignancies. Although the part of PAR1&2 in cancer is on the rise, their underlying signaling events are poorly understood. We review hereby past, present, and future cancer-associated PAR biology. Mainly, their role in physiological (placenta-cytotophobalst) and patho-physiological invasion processes. The identification and characterization of signal pleckstrin homology (PH)-domain-binding motifs established critical sites for breast cancer growth in PAR1&2. Among the proteins found to harbor important PH-domains and are involved in PAR biology are Akt/PKB as also Etk/Bmx and Vav3. A point mutation in PAR2, H349A, but not R352A, abrogated PH-protein association and is sufficient to markedly reduce PAR2-instigated breast tumor growth in vivo as also placental extravillous trophoblast (EVT) invasion in vitro is markedly reduced. Similarly, the PAR1 mutant hPar1-7A, which is unable to bind PH-domain, inhibits mammary tumors and EVT invasion, endowing these motifs with physiological significance and underscoring the importance of these previously unknown PAR1 and PAR2 PH-domain-binding motifs in both pathological and physiological invasion processes.
98. Effect of active fraction of Eriocaulon sieboldianum on human leukemia K562 cells via proliferation inhibition, cell cycle arrest and apoptosis induction.
作者: Yanhua Fan.;Hongyuan Lu.;Li An.;Changli Wang.;Zhipeng Zhou.;Fan Feng.;Hongda Ma.;Yongnan Xu.;Qingchun Zhao.
来源: Environ Toxicol Pharmacol. 2016年43卷13-20页
Eriocaulon sieboldianum (Sieb. & Zucc. ex Steud.), a genus of Eriocaulon in the Eriocaulaceae family, is an edible and medicinal plant used in traditional Chinese medicine. It was processed into healthcare beverages for expelling wind-heat, protecting eyes, and reducing blood fat. Also, it has been used with other herbs as Traditional Chinese herbal compound to treat cancer as adjuvants in tumor therapy in China. However, the active fractions and precise cellular mechanisms of E. sieboldianum extract remain to be illustrated. The goal of this study was to investigate the effects of the active fraction of E. sieboldianum on the growth of K562 cells and understand the possible mechanisms of its action. Our findings suggested that the fraction E3 of E. sieboldianum could effectively inhibit the activity of Aurora kinase and induce apoptosis via blocking cell cycle, up-regulating the expression of proapoptotic proteins including p53 and Bax and reducing the expression of Bcl-2. The levels of Cytochrome C, cleaved caspase-9, cleaved caspase-3 and cleaved PARP were also found to be increased after treatment with fraction E3 of E. sieboldianum. This study could improve the development of E. sieboldianum and raise its application value in cancer adjuvant therapy. Considering it is both a dietary supplement and a traditional Chinese herbal medicine which exhibits anticancer activities, it can be developed into functional food.
99. Impact of image registration surrogates on the planning target volume geometry for bladder radiation therapy.
作者: Vickie Kong.;Maisie Kwan.;Susan Chen.;Joanne Moseley.;Tim Craig.;Peter Chung.;Tara Rosewall.
来源: Pract Radiat Oncol. 2016年6卷5期e187-e194页
The use of Lipiodol and cone beam computed tomography (CT) has facilitated the generation of patient-specific planning target volumes (PTV) to reduce irradiation of normal tissue. However, injecting Lipiodol to demarcate the target volume is an invasive procedure. Center of bladder (COB) and bladder wall surface (BWS) encompassed by the clinical target volume (CTV) are proposed to be the alternative noninvasive surrogates. This study examines the impact of using these 3 surrogates for image registration on the resultant geometry of patient-specific PTVs.
100. Anticancer agent 3-bromopyruvic acid forms a conjugate with glutathione.
作者: Izabela Sadowska-Bartosz.;Rafal Szewczyk.;Lukasz Jaremko.;Mariusz Jaremko.;Grzegorz Bartosz.
来源: Pharmacol Rep. 2016年68卷2期502-5页
3-Bromopyruvic acid (3-BP), a glycolytic inhibitor and a promising anticancer compound, induces oxidative stress and depletes cells of glutathione (GSH). The causes of GSH loss remain unclear. The aim of this study was to ascertain whether 3-BP forms a conjugate with glutathione.
|